Results 121 to 130 of about 4,836 (184)

Benefit-risk profiling of advanced therapies in moderate-to-severe ulcerative colitis: a clustered network meta-analysis. [PDF]

Front Pharmacol
Zhang X, Qian H, Yang L, Wang H, Sun G, Lin A.   +5 more
europepmc   +1 more source

Editorial: Risankizumab in Refractory Crohn's Disease-From Real-World Effectiveness to Strategic Positioning and Early Monitoring. Authors' Reply. [PDF]

Aliment Pharmacol Ther
Ferreiro-Iglesias R, Zabana Y, Barreiro-de Acosta M.   +2 more
europepmc   +1 more source

Development of IgA nephropathy following risankizumab therapy for psoriatic arthritis: a case report. [PDF]

CEN Case Rep
Yagasaki M, Yamada K, Koshida T, Takagi M, Saeki H, Ogiwara K, Kobayashi T, Kihara M, Gohda T, Suzuki Y.   +9 more
europepmc   +1 more source

Efficacy and safety of risankizumab in moderate to severe psoriasis: an updated systematic review and meta-analysis. [PDF]

Ann Med Surg (Lond)
Shuja H, Farhan K, Wamiq U, Khan MS, Tariq MB, Shakir S, Uzair M, Salomon I.   +7 more
europepmc   +1 more source

Comparative effectiveness of IL-12/23 and IL-23 inhibitors versus JAK inhibitors in patients with inflammatory bowel disease and hidradenitis suppurativa: a real-world propensity-matched analysis. [PDF]

Crohns Colitis 360
Hafez Y, Osman A, Syn WK, Shmais M.
europepmc   +1 more source

Dual Targeted Therapy With Risankizumab and Upadacitinib in Refractory Ulcerative Colitis. [PDF]

ACG Case Rep J
Srivoleti P, Dhillon N, Boneschansker L.
europepmc   +1 more source

The IL-23/-17 Axis in PsA: What Have We Learned in the Last 20 Years? [PDF]

Mediterr J Rheumatol
Theodoridou F, Katsouli O, Fragoulis GE.
europepmc   +1 more source

Sequential Paradoxical Eczema Following Interleukin-23, Interleukin-17, and Tyrosine Kinase 2 Inhibitors in a Single Psoriasis Patient. [PDF]

J Dermatol
Park S, Jo SJ.
europepmc   +1 more source

New Tuberculosis Infection and Reactivation of Tuberculosis in Patients with Psoriasis or Psoriatic Arthritis Receiving IL-23 Inhibitors: A Systematic Literature Review. [PDF]

Dermatol Ther (Heidelb)
Wang G, Youn SW, Chang CL, Saeki H.
europepmc   +1 more source

A shared immunological context underlying IgA nephropathy. [PDF]

CEN Case Rep
Shimizu A, Tsuboi N.
europepmc   +1 more source